CARsgen Therapeutics Holdings Limited (2171.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Zonghai Li
Listed since: Jun 18, 2021
Employees: 355

Market position

Day range

Current HK$13.29

HK$13.28HK$13.62

52-week range

Current HK$13.29

HK$10.87HK$28.60

Open: HK$13.53
Previous close: HK$13.53
Volume: 958K; 0.17× average
Average volume: 5.7M; Average daily volume
Market cap: 7.57B HKD
Beta: 0.26; Market reference 1
50-day average: HK$14.8312; -10.39% below average
200-day average: HK$16.5255; -19.58% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 6.3B CNY
P/E (TTM): -70.98×
P/B (TTM): 5.75×
P/S (TTM): 47.82×
EV / EBITDA: -30.9×
Earnings yield: -1.33%
Free cash flow yield: -3.30%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 59.69%
Operating margin: -119.90%
Net margin: -64.91%
Return on equity: -12.49%
Return on assets: -7.57%
Return on invested capital: -9.36%

Financial health

Debt / equity: 0.07×
Current ratio: 5.73×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

125.66M CNY+218.74%

Operating income

−104.21M CNY+87.11%

Net income

−97.86M CNY+87.74%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	125.66M CNY	39.43M CNY	—	—	25.81M CNY
Cost of goods sold	45.71M CNY	24.68M CNY	96.57M CNY	94.81M CNY	—
Gross profit	79.95M CNY	14.75M CNY	−96.57M CNY	−94.81M CNY	25.81M CNY
Research and development	245.36M CNY	466.19M CNY	661.66M CNY	680.3M CNY	501.72M CNY
Selling, general, and administrative	26.07M CNY	52.02M CNY	133.31M CNY	136.61M CNY	126.52M CNY
Operating expenses	184.16M CNY	822.94M CNY	767.65M CNY	881.3M CNY	599.72M CNY
Interest income	14.81M CNY	41.92M CNY	72.79M CNY	27.57M CNY	9.61M CNY
Interest expense	6.9M CNY	5.71M CNY	4.66M CNY	15.52M CNY	10.87M CNY
Depreciation and amortization	23.99M CNY	65.14M CNY	67.41M CNY	56.92M CNY	52.45M CNY
Operating income	−104.21M CNY	−808.19M CNY	−767.65M CNY	−881.3M CNY	−573.91M CNY
Net income	−97.86M CNY	−798.13M CNY	−747.79M CNY	−892.25M CNY	−4.74B CNY